Clinical significance of Her2/neu overexpression in urothelial carcinomas

Romanian Journal of Morphology and Embryology

Volumn 51, Issue 2, 2010, Pages 277-282

  Alexa, Aurora ^a   Baderca, Flavia ^a   Zǎhoi, Delia Elena ^b   Lighezan, Rodica ^a   Izvernariu, D ^a   Raica, M ^a  

^a Department of Histology ^*  (Romania)

^b VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

HER2 neu; Immunohistochemistry; Trastuzumab; Upper urinary tract; Urothelial carcinomas

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BIOSYNTHESIS; BLADDER TUMOR; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; PATHOLOGY; UROTHELIUM;

FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; RECEPTOR, ERBB-2; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 77953053340     PISSN: 12200522     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ulrich A et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 1989, 244(4905):707-712.
2. Pegram MD, Slamon DJ, Combination therapy with trastu-zumab (Herceptin) and cisplatin for chemoresistant metas-tatic breast cancer: evidence for receptor-enhanced chemo-sensitivity, Semin Oncol, 1999, 26(4 Suppl 12):89-95.
3. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM, Humanization of an anti-p185HER2 antibody for human cancer therapy, Proc Natl Acad Sci U S A, 1992, 89(10):4285-4289.
4. Jimenez RE, Hussain M, Bianco FJ Jr, Vaishampayan U, Tabazcka P, Sakr WA, Pontes JE, Wood DP Jr, Grignon DJ, Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors, Clin Cancer Res, 2001, 7(8):2440-2447.
5. Lee SE, Chow NH, Chi YC, Tzai TS, Yang WH, Lin SN, Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer, Anticancer Res, 1994, 14(3B):1317-1324.
6. Tetu B, Fradet Y, Allard P, Veilleux C, Roberge N, Bernard P, Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer, J Urol, 1996, 155(5):1784-1788.
7. Mellon JK, Lunec J, Wright C, Home CH, Kelly P, Neal DE, C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value, J urol, 1996, 155(1):321-326.
8. Nguyen PL, Swanson PE, Jaszcz W, Aeppli DM, Zhang G, Singleton TP, Ward S, Dykoski D, Harvey J, Niehans GA, Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis, Am J Clin Pathol, 1994, 101(12):166-176.
9. Vollmer RT, Humphrey PA, Swanson PE, Wick MR, Hudson ML, Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2, Cancer, 1998, 82(4):715-723.
10. LIPPONEN P, ESKELINEN M, SYRJÄNEN S, TERVAHAUTA A, SyrjÄnen K, Use of immunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder, Eur Urol, 1991, 20(3):238-242.
11. Underwood M, Bartlett J, Reeves J, Gardiner DS, Scott R, Cooke T, C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors?, Cancer Res, 1995, 55(11):2422-2430.
12. Morgan BE, Salup R, Morgan MB, Differential C-erbB-2 and VEGF expression following BCG immunotherapy in superficial papillary transitional cell carcinoma of the bladder, Urol Oncol, 2002, 7(2):67-72.
13. Imai T, Kimura M, Takeda M, Tomita Y, Significance of epidermal growth factor receptor and c-erbB-2 protein expression in transitional cell cancer of the upper urinary tract for tumour recurrence at the urinary bladder, Br J Cancer, 1995, 71(1):69-72.
14. Fontana LO, García García F, Arcas Martínez Salas I, GARCÍA LIGERO J, TOMÁS ROS M, RICO GALIANO JL, Sempere Gutiérrez A, Canteras Jordana M., The expression of p53 and c-erb-2 in transitional cell carcinoma of the kidney pelvis and ureter and its relation to tumor progression and survival, Arch Esp Urol, 2002, 55(7):792-796.
15. WOOD DP Jr, Wartinger DD, Reuter V, CORDON-CARDO C, Fair WR, Chaganti RS, DNA, RNA, and immunohisto-chemical characterization of the HER-2/neu oncogene in transitional cell carcinoma of the bladder, J Urol, 1991, 146(5):1398-1401.
16. Coombs LM, Pigott DA, Sweeney E, Proctor AJ, Eydmann ME, Parkinson C, Knowles MA, Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder, Br J Cancer, 1991, 63(4):601-608.
17. Sauter G, Moch H, Moore D, Carroll P, Kerschmann R, Chew K, Mihatsch MJ, Gudat F, Waldman F, Heterogeneity of erbB-2 gene amplification in bladder cancer, Cancer Res, 1993, 53(10 Suppl):2199-2203.
18. BERGER MS, GREENFIELD C, GULLICK WJ, HALEY J, Downward J, Neal DE, Harris AL, Waterfield MD, Evaluation of epidermal growth factor receptors in bladder tumours, Br J Cancer, 1987, 56(5):533-537.
19. COUSSENS L, YANG-FENG TL, LIAO YC, CHEN E, GRAY A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U et al., Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene, Science, 1985, 230(4730):1132-1139.
20. Hung MC, Lau YK, Basic science of HER-2/neu: a review, Semin Oncol, 1999, 26(4 Suppl 1):51-59.
21. PEGRAM MD, PIENKOWSKI T, NORTHFELT DW, EIERMANN W, Patel R, Fumoleau P, Quan E, CROWN J, TOPPMEYER D, Smylie M, Riva A, Blitz S, Press MF, Reese D, Lindsay MA, Slamon DJ, Results of two open-label, multi-center phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer, J Natl Cancer Inst, 2004, 96(10):759-769.
22. PEGRAM MD, KONECNY GE, O'CALLAGHAN C, BERYT M, Pietras R, Slamon DJ, Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer, J Natl Cancer Inst, 2004, 96(10):739-749.
23. PEGRAM M, HSU S, LEWIS G, PIETRAS R, BERYT M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D, Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers, Oncogene, 1999, 18(13):2241-2251.
24. Mellon K, Thompson S, Charlton RG, Marsh C, Robinson M, Lane DP, Harris AL, Horne CH, Neal DE, p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate, J Urol, 1992, 147(2):496-499.
25. Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson KI, Osman I, Agus D, Scher HI, A Phase II trial of Herceptin alone and with Taxol for the treatment of prostate cancer, Proc Am Soc Clin Oncol, 2000, 19:Abstract 330.
26. Lönn U, Lönn S, Friberg S, Nilsson B, Silfverswärd C, Stenkvist B, Prognostic value of amplification of c-erb-B2 in bladder carcinoma, Clin Cancer Res, 1995, 1(10):1189-1194.
27. Wester K, SJÖSTRÖM A, de la Torre M, Carlsson J, Malmström PU, HER-2 - a possible target for therapy of metastatic urinary bladder carcinoma, Acta Oncol, 2002, 41(3):282-288.